moatshark My

All holdings

Arrowhead Pharmaceuticals

ARWR

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$539k
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$81.51

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
0Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 0; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Arrowhead Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Arrowhead Pharmaceuticals
Polen Capital Management0.0%$539k$539kNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Arrowhead Pharmaceuticals
Bought or soldFiling
18 Aug 2026Perry Michael SDirector▼ Sold11,600$87.30$1.0mForm 4
18 Aug 2026Olukotun Adeoye YDirector▼ Sold2,000$86.96$174kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
30 September
Shares outstanding
141m at 30 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$290kSep ’13
$382kSep ’15
$31.4mSep ’17
$169mSep ’19
$138mSep ’21
$241mSep ’23
$829mSep ’25
Sep ’13: $290k; Sep ’14: $175k; Sep ’15: $382k; Sep ’16: $158k; Sep ’17: $31.4m; Sep ’18: $16.1m; Sep ’19: $169m; Sep ’20: $88.0m; Sep ’21: $138m; Sep ’22: $243m; Sep ’23: $241m; Sep ’24: $3.6m; Sep ’25: $829m
Arrowhead Pharmaceuticals revenue and net income by year
YearRevenueNet income
Year to Sep 2025$829m−$1.6m
Year to Sep 2024$3.6m−$599m
Year to Sep 2023$241m−$205m
Year to Sep 2022$243m−$176m
Year to Sep 2021$138m−$141m
Year to Sep 2020$88.0m−$84.6m
Year to Sep 2019$169m$68.0m
Year to Sep 2018$16.1m−$54.5m
Year to Sep 2017$31.4m−$34.4m
Year to Sep 2016$158k−$81.7m
Year to Sep 2015$382k−$91.9m
Year to Sep 2014$175k−$58.6m
Year to Sep 2013$290k−$31.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.